Figure 2.

Gli1 loss impairs Sulf2-potentiated, DEN-induced liver tumorigenesis in transgenic mice. A, schematic depicting the experimental design of DEN-induced liver tumorigenesis studies. DEN is administered intraperitoneally on day 14, and the mouse is sacrificed at 8 months of age. B, validation of Gli1 knockout by qPCR of liver tissue from Gli1 HET (n = 3) and KO (n = 3) mice relative to WT (n = 3). Results are expressed as mean ± S.E. (error bars). C, three representative examples of liver tissue from DEN-treated mice with the indicated genotypes. Individual tumors are outlined in white. A 1-cm scale for each image is depicted in the bottom left corner. D, representative images of histopathological analysis of tumors derived from DEN-treated mice with the indicated genotypes. E, quantitative assessments of tumor burden (number, volume, weight, and tumor/liver weight ratio) with data points representing individual mice. Bars, mean ± S.E. F, percentage of mice in each genotype determined to have metastatic disease (lesions outside the liver).